Maria Pia Sormani1, Irene Schiavetti2, Doriana Landi3, Luca Carmisciano2, Nicola De Rossi4, Cinzia Cordioli4, Lucia Moiola5, Marta Radaelli6, Paolo Immovilli7, Marco Capobianco8, Vincenzo Brescia Morra9, Maria Trojano10, Gioacchino Tedeschi11, Giancarlo Comi12, Mario Alberto Battaglia13, Francesco Patti14, Yara Dadalti Fragoso15, Sedat Sen16, Aksel Siva17, Roberto Furlan18, Marco Salvetti19. 1. Department of Health Sciences, University of Genoa, Genoa, Italy/IRCCS Ospedale Policlinico San Martino, Genoa, Italy. 2. Department of Health Sciences, University of Genoa, Genoa, Italy. 3. Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy. 4. Centro Sclerosi Multipla, ASST Spedali Civili di Brescia, Montichiari, Italy. 5. Department of Neurology, Multiple Sclerosis Center, IRCCS Ospedale San Raffaele, Milan, Italy. 6. Department of Neurology and Multiple Sclerosis Center, ASST 'Papa Giovanni XXIII', Bergamo, Italy. 7. Multiple Sclerosis Center, Ospedale Guglielmo da Saliceto, Piacenza, Italy. 8. Department of Neurology, Regional Referral Multiple Sclerosis Centre, University Hospital San Luigi, Torino, Italy. 9. University of Naples Federico II, Naples, Italy. 10. Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy. 11. Department of Advanced Medical and Surgical Sciences, University of Campania, Napoli, Italy. 12. Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, Milan, Italy. 13. Research Department, Italian Multiple Sclerosis Foundation, Genoa, Italy/Department of Life Sciences, University of Siena, Siena, Italy. 14. Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, Catania, Italy/Centro Sclerosi Multipla, Policlinico Catania, University of Catania, Catania, Italy. 15. Universidade Metropolitana de Santos, Santos, Brazil. 16. School of Medicine, Ondokuz Mayis University, Samsun, Turkey. 17. School of Medicine, Istanbul University, Cerrahpasa, Istanbul, Turkey. 18. Institute of Experimental Neurology, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milano, Italy/Italian Neuroimmunology Association-AINI, Florence, Italy. 19. Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy/Unit of Neurology, IRCCS Neuromed, Isernia, Italy.
Abstract
BACKGROUND: The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of the pandemic, serological tests became routinely available. OBJECTIVE: To evaluate the seroprevalence of anti-SARS-CoV-2 antibodies according to the use of disease-modifying therapy (DMT) in a subset of patients included in the MuSC-19 data set who had undergone a serological test. METHODS: We evaluated the association between positive serological test results and time elapsed since infection onset, age, sex, Expanded Disability Status Scale score, comorbidities and DMT exposure using a multivariable logistic model. RESULTS: Data were collected from 423 patients (345 from Italy, 61 from Turkey and 17 from Brazil) with a serological test performed during follow-up. Overall, 325 out of 423 tested patients (76.8%) had a positive serological test. At multivariate analysis, therapy with anti-CD20 was significantly associated with a reduced probability of developing antibodies after COVID-19 (odds ratio (OR) = 0.20, p = 0.002). CONCLUSION: Patients with MS maintain the capacity to develop humoral immune response against SARS-COV-2, although to a lesser extent when treated with anti-CD20 drugs. Overall, our results are reassuring with respect to the possibility to achieve sufficient immunization with vaccination.
BACKGROUND: The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of the pandemic, serological tests became routinely available. OBJECTIVE: To evaluate the seroprevalence of anti-SARS-CoV-2 antibodies according to the use of disease-modifying therapy (DMT) in a subset of patients included in the MuSC-19 data set who had undergone a serological test. METHODS: We evaluated the association between positive serological test results and time elapsed since infection onset, age, sex, Expanded Disability Status Scale score, comorbidities and DMT exposure using a multivariable logistic model. RESULTS: Data were collected from 423 patients (345 from Italy, 61 from Turkey and 17 from Brazil) with a serological test performed during follow-up. Overall, 325 out of 423 tested patients (76.8%) had a positive serological test. At multivariate analysis, therapy with anti-CD20 was significantly associated with a reduced probability of developing antibodies after COVID-19 (odds ratio (OR) = 0.20, p = 0.002). CONCLUSION: Patients with MS maintain the capacity to develop humoral immune response against SARS-COV-2, although to a lesser extent when treated with anti-CD20 drugs. Overall, our results are reassuring with respect to the possibility to achieve sufficient immunization with vaccination.
Authors: Katharine J Bar; Pamela A Shaw; Grace H Choi; Nicole Aqui; Andrew Fesnak; Jasper B Yang; Haideliza Soto-Calderon; Lizette Grajales; Julie Starr; Michelle Andronov; Miranda Mastellone; Chigozie Amonu; Geoff Feret; Maureen DeMarshall; Marie Buchanan; Maria Caturla; James Gordon; Alan Wanicur; M Alexandra Monroy; Felicity Mampe; Emily Lindemuth; Sigrid Gouma; Anne M Mullin; Holly Barilla; Anastasiya Pronina; Leah Irwin; Raeann Thomas; Risa A Eichinger; Faye Demuth; Eline T Luning Prak; Jose L Pascual; William R Short; Michal A Elovitz; Jillian Baron; Nuala J Meyer; Kathleen O Degnan; Ian Frank; Scott E Hensley; Donald L Siegel; Pablo Tebas Journal: J Clin Invest Date: 2021-12-15 Impact factor: 14.808
Authors: Sachin P Gadani; Maria Reyes-Mantilla; Larissa Jank; Samantha Harris; Morgan Douglas; Matthew D Smith; Peter A Calabresi; Ellen M Mowry; Kathryn C Fitzgerald; Pavan Bhargava Journal: EBioMedicine Date: 2021-10-16 Impact factor: 8.143
Authors: Joseph J Sabatino; Kristen Mittl; William M Rowles; Kira McPolin; Jayant V Rajan; Matthew T Laurie; Colin R Zamecnik; Ravi Dandekar; Bonny D Alvarenga; Rita P Loudermilk; Chloe Gerungan; Collin M Spencer; Sharon A Sagan; Danillo G Augusto; Jessa R Alexander; Joseph L DeRisi; Jill A Hollenbach; Michael R Wilson; Scott S Zamvil; Riley Bove Journal: JCI Insight Date: 2022-02-22
Authors: Joseph J Sabatino; Kristen Mittl; William Rowles; Kira Mcpolin; Jayant V Rajan; Colin R Zamecnik; Ravi Dandekar; Bonny D Alvarenga; Rita P Loudermilk; Chloe Gerungan; Collin M Spencer; Sharon A Sagan; Danillo G Augusto; Jessa Alexander; Jill A Hollenbach; Michael R Wilson; Scott S Zamvil; Riley Bove Journal: medRxiv Date: 2021-09-20